Immuneering (IMRX) Balance Sheet: Assets & Liabilities

Immuneering (IMRX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Immuneering reported total assets of $231.99M and total liabilities of $13.50M. Shareholders' equity was $218.48M, up 427.9% from $41.39M a year earlier. Total debt stood at $3.82M against $172.83M in cash and short-term investments, a net cash position of $169.01M. That puts debt-to-equity at 0.02, compared with 0.10 a year earlier.

Immuneering Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Immuneering Corporation (IMRX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	128.65	36.14	59.41	72.64	74.89	37.09	13.78
Short-Term Investments	44.19	0.00	26.26	32.89	74.31	0.00	0.00
Cash & Short-Term Investments	172.83	36.14	85.67	105.52	149.20	37.09	13.78
Accounts Receivable	0.00	0.00	0.00	0.01	0.25	0.50	0.21
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	3.41	3.44	3.42	3.21	2.89	0.14	0.07
Total Current Assets	176.25	39.59	89.08	108.75	152.33	37.73	14.06
Non-Current Assets
Property, Plant & Equipment (Net)	4.26	4.79	5.40	5.78	6.13	0.68	0.04
Long-Term Investments	44.18	0.00	0.00	0.00	1.00	0.00	0.00
Goodwill	6.69	6.69	6.69	6.69	6.70	0.00	0.00
Intangible Assets	0.32	0.35	0.38	0.41	0.44	0.00	0.00
Other Non-Current Assets	0.28	1.30	1.03	0.74	0.10	0.01	0.00
Total Non-Current Assets	55.74	13.13	13.50	13.62	14.37	0.69	0.04
Total Assets	231.99	52.71	102.58	122.37	166.70	38.42	14.10
Current Liabilities
Accounts Payable	1.54	1.96	2.11	3.15	1.39	1.48	0.29
Short-Term Debt	0.40	0.34	0.30	0.38	0.27	0.08	0.00
Accrued Liabilities	7.84	4.97	1.55	4.50	1.05	0.70	-
Other Current Liabilities	8.13	0.23	0.26	0.02	3.97	0.70	0.21
Total Current Liabilities	10.07	7.50	7.85	8.05	5.63	2.26	0.51
Non-Current Liabilities
Long-Term Debt	3.43	3.82	4.16	4.46	5.09	0.54	0.00
Other Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00	58.10	20.12
Total Non-Current Liabilities	3.43	3.82	4.16	4.46	5.09	58.65	20.12
Total Liabilities	13.50	11.33	12.01	12.52	10.72	60.90	20.63
Stockholders' Equity
Common Stock	0.06	0.03	0.03	0.03	0.03	0.00	0.00
Retained Earnings	-280.32	-224.30	-163.26	-109.79	-59.27	-25.74	-8.70
Accumulated Other Comprehensive Income	0.08	0.00	0.00	-0.03	-0.05	0.00	0.00
Additional Paid-in Capital	498.66	265.65	253.81	219.64	215.28	3.25	2.16
Shares Outstanding	64.65	31.05	29.27	26.42	26.32	-	-
Total Stockholders' Equity	218.48	41.39	90.58	109.85	155.98	-22.48	-6.53
Total Liabilities & Equity	231.99	52.71	102.58	122.37	166.70	38.42	14.10

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Immuneering Balance Sheet

How much debt does Immuneering have?

Immuneering had total debt of $3.82M as of Dec 31, 2025, against $172.83M in cash and short-term investments. Its debt-to-equity ratio was 0.02. Total debt was $4.16M a year earlier.

What are Immuneering's total assets?

Immuneering reported total assets of $231.99M as of Dec 31, 2025, up 340.1% from $52.71M a year earlier. Total liabilities were $13.50M.

What is Immuneering's shareholders' equity?

Immuneering's shareholders' equity was $218.48M as of Dec 31, 2025, or about $3.38 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition